Next Generation Gynecological Cancer Diagnostics Market, 2031
DUBLIN, April 27, 2022 /PRNewswire/ — The “Next Generation Gynecological Cancer Diagnostics Market – A Global Market and Regional Analysis: Focus on Technology, Product Type, End-User and Country Analysis – Analysis and Forecast, 2020-2031” report has been added to from ResearchAndMarkets.com offer.
In 2020, the Global Next Generation Gynecological Cancer Diagnostics Market was valued at $1,976.5 millionwho should reach $5,657.7 million by 2031, growing at a CAGR of 10.07% over the forecast period 2021-2031.
The purpose of this study is to obtain a comprehensive view of the Next Generation Gynecological Cancer Diagnostics market in terms of various influencing factors, such as recent trends, regulatory requirements, and technological advancements in the market. The study defines products and services used for next-generation gynecological cancer diagnosis to improve women’s prognosis and quality of life.
Molecular mutation profiling is essential for the identification and characterization of unique mutations to facilitate disease manifestation and progression. Comprehensive profiling of biological samples, especially blood and tissue, can help researchers and clinicians identify specific biomarkers that signify a particular disease.
The study aims to decipher the potential of next-generation gynecological cancer diagnostics in the field of research and diagnostics and its pivotal role in empowering the current genomic era to enable personalized medicine in routine care settings. .
The report includes an in-depth review of the major players and recent developments that have occurred in this market. Additionally, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis.
It also aims to address various aspects of the Global Next Generation Gynecological Cancer Diagnostics Market with the help of key factors driving the market, restraints, and challenges that may inhibit the overall market growth and current growth opportunities that will shape the future trajectory of market expansion.
In the research report, the market has been segmented into “product type”, “technology”, “indication”, “end user” and “regions”. Each of these segments covers market revenue inclination, underlying patterns, market snapshot over the projected years, and trends using analytics on primary and secondary data obtained.
The global market for next-generation gynecological cancer diagnostics is currently booming due to the presence of various juggernauts such as Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Illumina, Inc., Agilent Technologies, Inc. , BGI and PerkinElmer. Inc., as well as other medium and small medium enterprises, which provide a wide range of next-generation gynecological cancer diagnostic products and services to the market.
Several companies are trying to enter the market and stay competitive by adopting different strategies ranging from partnerships and collaborations to business expansions and product launches.
Main topics covered:
2 Scope of research
2.1 Key questions answered by the report
3 Research methodology
3.1 Global Next Generation Gynecological Cancer Diagnostics Market: Research Methodology
3.2 Data sources
3.3 Market estimation model
3.4 Business profiling criteria
4.2 Molecular profiling and techniques
4.3 Role of molecular diagnostics in gynecological cancers
4.4 Chronology of diagnostic technologies and regulatory benchmarks in gynecological cancers
4.5 Emerging molecular tests in gynecological cancer
4.6 Current Market Size and Growth Potential, USD Million, 2021-2031
5 Role of biomarkers in gynecological cancer
5.2 Predictive molecular tests in gynecological cancer
5.3 Companion Diagnostics (CDx)
6 Impact of COVID-19 on the Global Next Generation Gynecological Cancer Diagnostics Market
6.1 Impact on supply chain and operations
6.2 Impact of COVID-19: Global Next Generation Gynecological Cancer Diagnostics Market
6.3 Pre- and post-COVID-19 impact assessment
7 Market dynamics
7.2 Impact analysis
7.3 Market Drivers
7.3.1 Further decline in the cost of next-generation sequencing (NGS)
7.3.2 Increase in Recommendations from Governmental Organizations and Scientific Societies
7.3.3 Increased Awareness and Transition to Personalized Medicine
7.4 Market Constraints
7.4.1 Next Generation Sequencing (NGS) Tests Approved by the Limited Food and Drug Administration (FDA)
7.4.2 Complexities related to the overall Next Generation Sequencing (NGS) process and the interpretation of results
7.4.3 Reimbursement challenges in countries
7.5 Market Opportunities
7.5.1 Increased market investment and government-funded projects
7.5.2 Acceptance of next generation sequencing (NGS) by emerging countries
8 Industry Outlook
8.2 Legal requirements and framework in the United States
8.2.1 FDA regulations
8.2.2 CMS regulations
8.3 Legal requirements and framework in Europe
8.4 Legal requirements and framework in Asia Pacific
8.5 Refund Scenario
8.6 Funding Scenario
9.1 Global Next-Generation Gynecological Cancer Diagnostics Market (by Technology), USD Million, 2020-2031
18.104.22.168 Polymerase chain reaction (PCR)
22.214.171.124.1 by value
126.96.36.199.2 by volume
188.8.131.52 Next Generation Sequencing (NGS)
184.108.40.206.1 by value
220.127.116.11.2 by volumes
18.104.22.168.3 Wide panels
22.214.171.124.4 Targeted gene panels
126.96.36.199.5 Single gene panels
188.8.131.52 Other technologies
10 Global Next Generation Gynecological Cancer Diagnostics Market (by Product Type), USD Million, 2020-2031
11 Global Next-Generation Gynecological Cancer Diagnostics Market (by Indication), USD Million, 2020-2031
11.2 Ovarian cancer
11.3 Cervical cancer
11.4 Uterine cancer
12 Global Next Generation Gynecological Cancer Diagnostics Market (by End User), USD Million, 2020-2031
12.2 Academic and research institutes
12.3 Hospitals and outpatient centers
12.4 Diagnostic Laboratories
12.5 Other end users
13 Global Next Generation Gynecological Cancer Diagnostics Market (by Region), USD Million, 2020-2031
13.2 North America
13.2.1 United States
13.3.2 United Kingdom
13.3.7 Rest ofEurope
13.4 Asia Pacific
13.4.5 South Korea
13.4.6 Rest ofAsia Pacific
13.5 Latin America
13.5.3 Rest ofLatin America
13.6 Rest of the world (right of way)
14 Competitive Landscape and Company Profiles
14.1 Competitive Landscape
14.2 Regulatory and legal activities
14.3 Synergistic Activities
14.4 Mergers and Acquisitions
14.5 Product launches
14.6 Business expansions
14.7 Market Share Analysis, by Service Providers, 2020
14.8 Market Share Analysis, By Product Manufacturers, 2020
14.9 Growth Share Analysis, by Company, 2019-2020
15 company profiles
- Agilent Technologies, Inc.
- ARUP Laboratories
- BGI Genomics
- CENTOGENE SA
- F. Hoffmann-La Roche SA
- Fulgent Genetics, Inc.
- Illumina, Inc.
- Invitee Corporation
- Konica Minolta, Inc.
- Laboratory Corporation of America Holdings
- Myriad Genetics, Inc.
- OPKO Health, Inc.
- QIAGEN AG
- Quest Diagnostics Incorporated
- Thermo Fisher Scientific Inc.
For more information on this report, visit https://www.researchandmarkets.com/r/wzt7nh
Research and Markets
For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900
US Fax: 646-607-1904
Fax (outside the US): +353-1-481-1716
SOURCE Research and Markets